Marlene L Durand1, Claes H Dohlman. 1. Infectious Disease Unit, Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital, Boston, MA 02114, USA. mdurand@partners.org
Abstract
PURPOSE: To determine the influence of topical vancomycin prophylaxis on the incidence of bacterial endophthalmitis in eyes with a Boston Keratoprosthesis (KPro). METHODS: A retrospective chart review was performed for 255 eyes of 231 patients who received a KPro between March 1990 and December 2006. Preoperative diagnoses were burn, ocular cicatricial pemphigoid (OCP), Stevens-Johnson Syndrome (SJS), and graft failure/other. Patients used topical antibiotic prophylaxis for the duration of the KPro: polymyxin-trimethoprim or a quinolone in the 1990s, or a quinolone with or without vancomycin beginning in late 1999. For each KPro eye, the follow-up interval was divided into months on or off vancomycin (vancomycin versus no-vancomycin group). The incidence of endophthalmitis was calculated with Kaplan-Meier survival curves. RESULTS: The 255 eyes were followed for 673.6 patient-years (mean, 2.64 years; range, 1 week to 13 years). There were 18 cases of bacterial endophthalmitis; 17 occurred at least 6 weeks postoperatively (range, 1.5 to 46 months). Gram-positive cocci caused over 80% of cases. Only 1 case, due to an atypical mycobacterium, occurred in a patient using vancomycin.The incidence of bacterial endophthalmitis was lower in the vancomycin group than in the no-vancomycin group: 0.35% versus 4.13% per patient-year (P = 0.001). It was also lower in SJS eyes using vancomycin versus no vancomycin: 1.76% versus 18.39% per patient-year (P = 0.009). In eyes with preoperative diagnoses of burn, OCP, or graft failure/other, the incidence in the vancomycin group was zero. CONCLUSION: Topical vancomycin plus a quinolone is effective in preventing bacterial endophthalmitis in KPro eyes.
PURPOSE: To determine the influence of topical vancomycin prophylaxis on the incidence of bacterial endophthalmitis in eyes with a Boston Keratoprosthesis (KPro). METHODS: A retrospective chart review was performed for 255 eyes of 231 patients who received a KPro between March 1990 and December 2006. Preoperative diagnoses were burn, ocular cicatricial pemphigoid (OCP), Stevens-Johnson Syndrome (SJS), and graft failure/other. Patients used topical antibiotic prophylaxis for the duration of the KPro: polymyxin-trimethoprim or a quinolone in the 1990s, or a quinolone with or without vancomycin beginning in late 1999. For each KPro eye, the follow-up interval was divided into months on or off vancomycin (vancomycin versus no-vancomycin group). The incidence of endophthalmitis was calculated with Kaplan-Meier survival curves. RESULTS: The 255 eyes were followed for 673.6 patient-years (mean, 2.64 years; range, 1 week to 13 years). There were 18 cases of bacterial endophthalmitis; 17 occurred at least 6 weeks postoperatively (range, 1.5 to 46 months). Gram-positive cocci caused over 80% of cases. Only 1 case, due to an atypical mycobacterium, occurred in a patient using vancomycin.The incidence of bacterial endophthalmitis was lower in the vancomycin group than in the no-vancomycin group: 0.35% versus 4.13% per patient-year (P = 0.001). It was also lower in SJS eyes using vancomycin versus no vancomycin: 1.76% versus 18.39% per patient-year (P = 0.009). In eyes with preoperative diagnoses of burn, OCP, or graft failure/other, the incidence in the vancomycin group was zero. CONCLUSION: Topical vancomycin plus a quinolone is effective in preventing bacterial endophthalmitis in KPro eyes.
Authors: Maria Fideliz de la Paz; Josef Stoiber; Valeria de Rezende Couto Nascimento; Juan Alvarez de Toledo; Orang Seyeddain; Wolfgang Hitzl; Günther Grabner; Rafael I Barraquer; Ralph Michael Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-10-25 Impact factor: 3.117
Authors: Irmgard Behlau; Koushik Mukherjee; Amit Todani; Ann S Tisdale; Fabiano Cade; Liqiang Wang; Elizabeth M Leonard; Fouad R Zakka; Michael S Gilmore; Frederick A Jakobiec; Claes H Dohlman; Alexander M Klibanov Journal: Biomaterials Date: 2011-09-07 Impact factor: 12.479
Authors: Liqiang Wang; Kyung Jae Jeong; Homer H Chiang; David Zurakowski; Irmgard Behlau; James Chodosh; Claes H Dohlman; Robert Langer; Daniel S Kohane Journal: Invest Ophthalmol Vis Sci Date: 2011-09-22 Impact factor: 4.799
Authors: Jose L Güell; Edilio Arcos; Oscar Gris; Diego Aristizabal; Miguel Pacheco; Claudia L Sanchez; Felicidad Manero Journal: Saudi J Ophthalmol Date: 2011-04-30
Authors: Alja Crnej; Masahiro Omoto; Thomas H Dohlman; John M Graney; Claes H Dohlman; Brigita Drnovsek-Olup; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2014-05-15 Impact factor: 4.799